HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Raises Price Target to $42
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Andrew S. Fein maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $32 to $42.
HC Wainwright & Co. analyst Andrew S. Fein maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $32 to $42.